3Schneider J. Tumor markers in detection of lung cancer [J]. Advclinchem, 2006,42 : 1-41.
4Oremek GM, Sauer-eppel H, Bruzdziak TH. Value of tumor and inflammatorymarkers in lung cancer[J]. An- ticancer Res, 2007, 27..1911-1915.
5Cho WC. Potentially useful biomarkers {or the diagno- sis, treatment and prognosis of lung cancer[J]. Biomed Pharmacother, 2007,61 .. 515-519.
6Hatkazis KD, Froudarakis ME, Bouros D, et al. Prog- nostic value of serum tumor markers in patients with lung cancer rJ]. Respiration, 2002,69:25-29.
7Ebert W, Muley T, Trainer R, et al. Comparision of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with small cell lung eaneer[J']. Antieaneer RES,2002,22(8): 1083.
10Molina R, Filella X, Auge JM, et al. Tumor markers ( cea, ca 125, cyfra 21-1 ,scc and nse) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors[ J]. Tumour Biol, 2003,24 : 209.
5Nisman B,Biran H,Heching N. Prognostic role of ser-um cytokeratin 19 fragments in advanced non-small-cell lung cancer:association of marker changes after two chemo-therapy cycles with different measures of clinical response and survival[J].{H}British Journal of Cancer,2008,(01):77-79.
6Cedrés S,Nu?ez I,Longo M. Serum tumor markers CEA,CYFRA21-1,and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J].Clin Lung Cancer,2011,(03):172-179.
7Ferroni P,Martini F,Portarenal I,et al.Novel highsensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients[J].Clin Lung Cancer,2012,13:482-487.
